[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-344450-en":59,"doc-seo-344450-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},344450,13056703020460,"Valentina","https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Can DNA Methylation in Peritumoral and Contralateral Breast Tissue Predict Recurrence or Second Breast Cancers? - Academic article overview","Despite major advances in early breast cancer detection and therapeutic strategies, locoregional and distant recurrences and the emergence of a second primary breast cancer remain difficult clinical problems. Current prognostic tools depend largely on tumor-specific factors and, more recently, molecular signatures, yet they still perform imperfectly. This work focuses on DNA methylation changes in adjacent peritumoral and contralateral non-tumoral breast tissue, reflecting field cancerization, and evaluates their potential as predictive biomarkers for recurrence while emphasizing the need for confirmation in large prospective trials.","Perspective  \nCan DNA Methylation in Peritumoral and Contralateral Breast Tissue Predict Recurrence or Second Breast Cancers?  \nJennifer Hammer, Marie Malvaux, Louise van Drooghenbroeck, Cédric Van Marcke, Francois P. Duhoux  and Martine Berliere *  \nAcademic Editor: Adam G. Marsh  \nReceived: 20 March 2026  \nRevised: 22 April 2026  \nAccepted: 28 April 2026  \nPublished: 30 April 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nBreast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, 1200 Woluwe-Saint-Lambert, Belgium; jennifer.hammer@saintluc.uclouvain.be (J.H.);  \n[marie.malvaux@cspo.be](marie.malvaux@cspo.be) (M.M.); [ldroogh2@clstjean.be](ldroogh2@clstjean.be) (L.v.D.); [cedric.vanmarcke@saintluc.uclouvain.be](cedric.vanmarcke@saintluc.uclouvain.be) (C.V.M.);  \n[francois.duhoux@saintluc.uclouvain.be](francois.duhoux@saintluc.uclouvain.be) (F.P.D.)  \n* Correspondence: martine.berliere@saintluc.uclouvain.be  \nAbstract  \nDespite major advances in early breast cancer detection and therapeutic strategies, locoregional and distant recurrences, as well as the development of a second primary breast cancer, remain major clinical challenges. Current prognostic tools primarily rely on tumorspecific features, such as the histological grade, hormone receptor status, and proliferative index, and, more recently, on molecular signatures aimed at improving risk stratification and predicting recurrence. However, these approaches remain imperfect, and there is an urgent need to develop complementary strategies. Growing attention has been focused on the tumor microenvironment and the surrounding non-tumoral tissue, which may harbor clinically relevant molecular alterations. Emerging evidence suggests that DNA methylation changes can be detected in the adjacent and contralateral breast tissue and reflect early steps of carcinogenesis or predisposition to tumor development. This phenomenon, often referred to as field cancerization, raises new questions about the dynamics of cancer development. The aim of this work is to provide an integrative overview of DNA methylation alterations in normal breast tissue, including peritumoral and contralateral areas, and to examine their potential as predictive biomarkers of recurrence, based on the available data from tumoral tissue. In theory, these applications seem promising, but their role needs to be confirmed in large prospective trials, in order to overcome barriers to clinical implementation. The currently available evidence does not support a role for DNA methylation in the selection of locoregional and systemic treatment strategies, particularly with a view to reducing the rising number of uni-and bilateral mastectomies performed without any demonstrated survival benefit.  \nKeywords: breast cancer; predictive factors of local recurrence; risk of contralateral breast cancer; field cancerization; tumor microenvironment; DNA methylation  \n1. Introduction  \nBreast cancer is the most commonly diagnosed cancer among women globally and remains an important cause of cancer-related mortality [1] . Despite significant progress in early detection and therapeutic advances that have improved overall survival, recurrence remains a major clinical challenge. Recurrence comprises local recurrence, distant recurrence, and contralateral breast cancer (CBC), which is a new breast cancer. The risk of local recurrence after breast-conserving surgery (1 to 1.5% per year) and the risk of CBC  \n(1% per year) are low among the general population of breast cancer patients [2] . However, some subgroups of patients exhibit a higher risk of local recurrence and/or CBC [3–6] . Distant recurrence occurs in up to 15 to 30% of patients, depending on the tumor subtype and initial staging [7] . Current prognostic t","cbCaiq53E6bObobv","https://ap.wps.com/l/cbCaiq53E6bObobv","pdf",739437,17,"English","en",105,"# Abstract\n# Introduction\n# Keywords","[{\"question\":\"Why are current prognostic tools for breast cancer recurrence still considered insufficient?\",\"answer\":\"They mainly rely on tumor-specific features and molecular signatures, but these approaches remain imperfect at predicting recurrence, especially in early-stage or low-risk disease.\"},{\"question\":\"What is the study’s main focus regarding DNA methylation?\",\"answer\":\"It provides an integrative overview of DNA methylation alterations in normal breast tissue, particularly peritumoral and contralateral areas, and assesses their potential predictive value for recurrence.\"},{\"question\":\"What clinical steps does the document emphasize before DNA methylation can be used in practice?\",\"answer\":\"Its role must be confirmed in large prospective trials to overcome barriers to clinical implementation, and current evidence does not yet support using DNA methylation to guide treatment selection.\"}]","Can DNA Methylation in Peritumoral and Contralateral Breast Tissue Predict Recurrence or Second Breast Cancers? - Academic article overview | PDF",1790053814,43,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b2ba2f65b936a4320d521886405232d.webp",983,1390,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6b5a4788e81899e18641c104c9db037.webp",982,1388,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2d761be88d8916a5362aa3e88269def.webp",981,1387,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06a6bd5b91fb7168ee77d2e646a9dc74.webp",980,1385,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"can-dna-methylation-in-peritumoral-and-contralateral-breast-tissue-predict-recurrence-or-second-breast-cancers-academic-article-overview","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/can-dna-methylation-in-peritumoral-and-contralateral-breast-tissue-predict-recurrence-or-second-breast-cancers-academic-article-overview/344450/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/can-dna-methylation-in-peritumoral-and-contralateral-breast-tissue-predict-recurrence-or-second-breast-cancers-academic-article-overview/344450.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":136,"interactionType":137,"userInteractionCount":34},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"Why are current prognostic tools for breast cancer recurrence still considered insufficient?","Question",{"text":146,"@type":147},"They mainly rely on tumor-specific features and molecular signatures, but these approaches remain imperfect at predicting recurrence, especially in early-stage or low-risk disease.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"What is the study’s main focus regarding DNA methylation?",{"text":151,"@type":147},"It provides an integrative overview of DNA methylation alterations in normal breast tissue, particularly peritumoral and contralateral areas, and assesses their potential predictive value for recurrence.",{"name":153,"@type":144,"acceptedAnswer":154},"What clinical steps does the document emphasize before DNA methylation can be used in practice?",{"text":155,"@type":147},"Its role must be confirmed in large prospective trials to overcome barriers to clinical implementation, and current evidence does not yet support using DNA methylation to guide treatment selection.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1790188866]